CLINICAL RESEARCH: CLINICAL TRIAL
Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure
A Randomized, Double-Blind, Placebo-Controlled Trial
Piotr Ponikowski, MD, PhD*,3,6,
Stefan D. Anker, MD, PhD , ,1,3,4,6,
Joanna Szachniewicz, MD*,
Darlington Okonko, BSc, MRCP,2,
Mark Ledwidge, PhD ,
Robert Zymlinski, MD*,
Enda Ryan, MRCP,
Scott M. Wasserman, MD||,
Nigel Baker, MSc||,5,
Dylan Rosser, BSc||,5,
Stuart D. Rosen, MD,
Philip A. Poole-Wilson, MD,
Waldemar Banasiak, MD, PhD*,
Andrew J.S. Coats, DM¶,3,4 and
Ken McDonald, MD,3,*
* Cardiac Department, Military Hospital, Wroclaw, Poland
Clinical Cardiology, National Heart and Lung Institute, Imperial College London, London, England
Division of Applied Cachexia Research, Department of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany
Department of Cardiology, St. Vincent’s University Hospital, Elm Park, Dublin, Ireland
|| Amgen Limited, 240 Cambridge Science Park, Cambridge, England
¶ Faculty of Medicine, University of Sydney, Sydney, Australia.
Manuscript received June 14, 2006;
revised manuscript received August 30, 2006,
accepted September 11, 2006.
* Reprint requests and correspondence: Dr. Ken McDonald, St. Vincent’s University Hospital, Elm Park, Dublin 4, Ireland. (Email: kenneth.mcdonald{at}ucd.ie).
OBJECTIVES: This study sought to investigate whether darbepoetin alfa, an erythropoiesis-stimulating protein (ESP), improves exercise capacity in patients with symptomatic chronic heart failure (CHF) and anemia.
BACKGROUND: Anemia is common in patients with CHF.
METHODS: In a multicenter, randomized, double-blind, placebo-controlled study, CHF patients with anemia (hemoglobin  9.0 to  12.0 g/dl) received subcutaneous placebo (n = 22) or darbepoetin alfa (n = 19) at a starting dose of 0.75 µg/kg every 2 weeks for 26 weeks. The primary end point was change in exercise tolerance from baseline to week 27 as measured by peak oxygen uptake (ml/min/kg body weight). Other end points included changes in absolute peak VO
2 (ml/min), exercise duration, and health-related quality of life.
RESULTS: Differences (95% confidence interval) in mean changes from baseline to week 27 between treatment groups were 1.5 g/dl (0.5 to 2.4) for hemoglobin concentration (p = 0.005), 0.5 ml/kg/min (–0.7 to 1.7) for peak VO
2 (p = 0.40), 45 ml/min (–35 to 127) for absolute peak VO
2 (p = 0.27), and 108 s (–11 to 228) for exercise duration (p = 0.075). Patients receiving darbepoetin alfa compared with placebo had an improvement in self-reported Patient’s Global Assessment of Change (79% vs. 41%, p = 0.01) but no significant differences in the Kansas City Cardiomyopathy and Minnesota Living with Heart Failure Questionnaire scores. Darbepoetin alfa was well tolerated.
CONCLUSIONS: In patients with symptomatic CHF and anemia, darbepoetin alfa increased and maintained hemoglobin concentrations and improved health-related quality of life. A trend toward increased exercise time but not peak VO
2 was observed. (Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia; http://clinicaltrials.gov/ct/show/NCT00117234?order = 1; NCT00117234
[ClinicalTrials.gov]
).
|
Abbreviations and Acronyms
| | BNP = brain natriuretic peptide concentration | | CHF = chronic heart failure | | CI = confidence interval | | ESP = erythropoiesis-stimulating protein | | KCCQ = Kansas City Cardiomyopathy Questionnaire | | LVEF = left ventricular ejection fraction | | MLHFQ = Minnesota Living With Heart Failure Questionnaire | | NYHA = New York Heart Association | | PGA = Patient’s Global Assessment of Change | | VO
2
= oxygen uptake per kilogram body weight |
|
Related Article
-
Anemia in Chronic Heart Failure: Should We Treat It and How?
- Michel Komajda
J. Am. Coll. Cardiol. 2007 49: 763-764.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S. D. Anker and R. Toto
Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients
NDT Plus,
January 1, 2009;
2(suppl_1):
i3 - i8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Silverberg, D. Wexler, A. Iaina, and D. Schwartz
The Role of Correction of Anemia in Patients With Congestive Heart Failure Associated with Chronic Kidney Failure
Journal of Pharmacy Practice,
December 1, 2008;
21(6):
420 - 423.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Rastogi, M. Imai, V. G. Sharov, S. Mishra, and H. N. Sabbah
Darbepoetin-{alpha} prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure
Am J Physiol Heart Circ Physiol,
December 1, 2008;
295(6):
H2475 - H2482.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, et al.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)
Eur. Heart J.,
October 1, 2008;
29(19):
2388 - 2442.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Courneya, L. W. Jones, C. J. Peddle, C. M. Sellar, T. Reiman, A. A. Joy, N. Chua, L. Tkachuk, and J. R. Mackey
Effects of Aerobic Exercise Training in Anemic Cancer Patients Receiving Darbepoetin Alfa: A Randomized Controlled Trial
Oncologist,
September 1, 2008;
13(9):
1012 - 1020.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Anand
Anemia and Chronic Heart Failure: Implications and Treatment Options
J. Am. Coll. Cardiol.,
August 12, 2008;
52(7):
501 - 511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kazory and E. A. Ross
Contemporary Trends in the Pharmacological and Extracorporeal Management of Heart Failure: A Nephrologic Perspective
Circulation,
February 19, 2008;
117(7):
975 - 983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Ghali, I. S. Anand, W. T. Abraham, G. C. Fonarow, B. Greenberg, H. Krum, B. M. Massie, S. M. Wasserman, M.-L. Trotman, Y. Sun, et al.
Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia
Circulation,
January 29, 2008;
117(4):
526 - 535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Toblli, A. Lombrana, P. Duarte, and F. Di Gennaro
Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency
J. Am. Coll. Cardiol.,
October 23, 2007;
50(17):
1657 - 1665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Francis and A. Kanderian
Anemia and Heart Failure: A New Pathway?
J. Am. Coll. Cardiol.,
October 23, 2007;
50(17):
1666 - 1667.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. van Veldhuisen, K. Dickstein, A. Cohen-Solal, D. J.A. Lok, S. M. Wasserman, N. Baker, D. Rosser, J. G.F. Cleland, and P. Ponikowski
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia
Eur. Heart J.,
September 2, 2007;
28(18):
2208 - 2216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Darbepoetin Alfa Tested in Anemic HF Patients
Journal Watch Cardiology,
March 6, 2007;
2007(306):
5 - 5.
[Full Text]
|
|
|
|
|
|
|
M. Komajda
Anemia in Chronic Heart Failure: Should We Treat It and How?
J. Am. Coll. Cardiol.,
February 20, 2007;
49(7):
763 - 764.
[Full Text]
[PDF]
|
|
|
|
